Articles

O.19 Overall survival improvement in metastatic clear-cell renal cell carcinoma patients from 2000 to 2020

BJMO - 2021, issue 3, march 2021

Sofie Demasure , Isabel Spriet , Philip R. Debruyne , Annouschka Laenen , Wim Wynendaele , Marcella Baldewijns , Herlinde Dumez , Paul M. Clement , Hans Wildiers , Patrick Schöffski , Eduard Rousse , Lisa Kinget , Maarten Albersen , Benoit Beuselinck

Introduction: Only a limited number of recent phase III studies with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), mTOR-inhibitors or immune checkpoint inhibitors (ICI) in metastatic clear-cell renal cell carcinoma (m-ccRCC) could show an overall survival (OS) benefit compared to standard of care. We aimed to study the evolution of OS of m-ccRCC patients during the last 20-years period (2000–2020).

Read more

P18 Retrospective analysis of the clinical presentation, treatment and outcome of angiosarcoma in a sarcoma referral center

BJMO - 2021, issue 3, march 2021

Thomas Meyskens , Iris Timmermans , Hans Wildiers , Herlinde Dumez , Daphne Hompes , Melissa Christiaens , Raf Sciot , Annouschka Laenen , Jerry Lee , Patrick Schöffski

Objective: Angiosarcoma (AS) is a rare, aggressive subtype of soft tissue sarcoma (STS). Treatment requires a multidisciplinary approach and should preferably be carried out in reference centers. We performed an in-depth analysis of patient characteristics, treatments and prognostic factors in patients (pts) with AS treated at the University Hospitals Leuven (Belgium).

Read more

O.04 PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOR (GIST)

BJMO - 12, issue 3, february 2018

Y. Wang , A. Wozniak PhD, Jasmien Wellens , Y. Gebreyohannes , Maria Jose Guillén , C.M. Galmarini , Pablo M. Avilés , Maria Debiec-Rychter , Raf Sciot , Patrick Schöffski

Read more
X